![]() Dang Quoc Hung, CEO/Managing Director of LiveSpo, expressed excitement about the opportunity to join the BIO International Convention 2023, stating, "Participating in the world's leading exhibition of breakthrough biotechnology solutions testifies to LiveSpo's readiness and competitiveness in the global pharmaceutical market. The Vietnamese representative will also host a booth and participate in thematic seminars to explore and remain updated on scientific and technological advancements in developed countries. Discussions will revolve around the potential and practical applications of breakthrough spore probiotics, as well as opportunities for exclusive distribution of LiveSpo products in international markets. During the BIO International Convention, LiveSpo Pharma will engage in B2B meetings with partners from various countries, including Turkey, the UK, Canada, Spain, Australia, Brazil, India, France, and others. It also presents a path towards "A Future Without Antibiotics", mitigating the persistent global health concern of antibiotic overuse. LiveSpo NAVAX addresses the treatment needs of 80 percent of children under two years old infected with RSV, a condition currently lacking a cure. Moreover, it offers an opportunity to promote breakthrough "Made in Vietnam" technology globally, providing safe and sustainable treatment options to more patients, particularly children. (Reference: ) The presence of LiveSpo NAVAX at the BIO International Convention 2023 signifies the leapfrog development of Vietnamese science in the probiotics industry, particularly spore probiotics technology, which has gained traction as a healthcare trend worldwide. The safety and remarkable efficacy of this product have been published in the esteemed Scientific Reports journal (Nature), and the article ranked among the top 100 most downloaded in 2022. LiveSpo NAVAX demonstrates an exceptional ability to reduce the load of Respiratory Syncytial Virus (RSV) by 600-fold and influenza virus by 900-fold. Its significant impact on reducing treatment duration for acute respiratory infections in children has been proven. After undergoing rigorous clinical trials aligned with US standards, LiveSpo NAVAX has emerged as the world's first spore probiotic nasal spray. ![]() This technology features liquid-form, multi-strain, high-concentration probiotics, including the flagship product LiveSpo NAVAX, a pre-active SPL spore probiotic delivered in the form of nasal spray. Nguyen Hoa Anh, R&D Director and Chairman of LiveSpo Pharma, will present LiveSpo's breakthrough spore probiotics technology at the BIO International Convention 2023. Among the 1,200 booths, LiveSpo Pharma proudly represents Vietnam as the sole participant, introducing "Made in Vietnam" spore probiotics technology for respiratory disease treatment. This year, the convention takes place from June 5 to 8 at the Boston Convention & Exhibition Center in Massachusetts, USA. It serves as a platform for biopharmaceutical companies, investors, and government leaders to exchange ideas, present research findings, and explore partnership opportunities in the field. The BIO International Convention, held annually in the United States in June, attracts approximately 14,000 attendees from 65 countries.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |